<DOC>
	<DOC>NCT01691755</DOC>
	<brief_summary>This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar monotherapy compared with placebo in patients with type 2 diabetes mellitus who have not previously received anti-hyperglycemic therapy. Patients will be randomized to receive oral doses of 150 mcg aleglitazar once daily or placebo. The anticipated time on study treatment is 26 weeks.</brief_summary>
	<brief_title>A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Diagnosis of diabetes mellitus, type 2 within 12 months prior to screening Patients who have not received a antihyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past HbA1c &gt;/=7% and &lt;/=9.5% at screening or within 4 weeks prior to screening and at prerandomization visit Fasting plasma glucose &lt;/=240 mg/dL at prerandomization visit Agreement to maintain diet and exercise habits during the study Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months Any previous treatment with thiazolidinedione or a dual peroxisome proliferator activated receptor (PPAR) agonist Any body weight lowering or lipoproteinmodifying therapy within 12 weeks prior to screening (except stable dose of statin) Symptomatic congestive heart failure classified as New York Heart Association class IIIV at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>